Who is Dr. Brooks, Urologist in Stanford, CA?
Dr. James Brooks, MD is an Urologist, who primarily practices in Stanford, CA with 2 additional practice locations. He has been practicing for over 31 years and is board certified by the American Board of Urology. Dr. Brooks completed his residency at Emory Univ Hosp, Psychiatry; Med Coll Of Ga Hosp & Cli, General Surgery. Dr. Brooks is fluent in English, and is currently seeing new patients. Dr. Brooks’s practice accepts Medicaid, Medicare, UnitedHealthcare, Aetna, Cigna and other major insurance plans. To book an appointment or to confirm insurance options, please call Dr. Brooks’s office at (650) 723-4000.
What are Areas of Expertise for Dr. Brooks?
Dr. James Brooks, MD is a highly-rated, board-certified Urologist known for expertly diagnosing, treating, and managing a wide array of related conditions or procedures. Utilizing the latest medical advancements and evidence-based practices, Dr. Brooks empowers patients to confidently navigate their health journey, specializing in Prostate Cancer, Urologic Cancer, or comprehensive wellness support. Serving the Stanford/CA community, Dr. Brooks is dedicated to enhancing lives through expert, patient-centered care.
Where did Dr. Brooks go to medical school and complete their residency?
Fellowship: Johns Hopkins University MD | Johns Hopkins University,Baltimore, Md, Usa
Residency: Emory Univ Hosp, Psychiatry; Med Coll Of Ga Hosp & Cli, General Surgery | Johns Hopkins Hospital | Johns Hopkins University | Johns Hopkins University Affiliated Hospitals | Johns Hopkins University Affiliated Hospitals
Medical School: Med Coll Of Ga Sch Of Med
Is Dr. Brooks board certified in Urologist?
Yes, Dr. James Brooks, MD is board certified by the American Board of Urology , American Board of Urology since 2000, American Board of Urology since 2009
What languages does Dr. Brooks speak?
Dr. Brooks and their clinical team can communicate with patients in the following languages:
English
What conditions does Dr. Brooks treat?
As a Urologist, Dr. Brooks diagnoses, treats, and manages a wide range of conditions. This condition information is derived from anonymized insurance claims and highlights the medical conditions most commonly treated by Dr. Brooks. It provides insight into the doctor’s areas of experience and expertise based on real-world patient encounters from the past two years, updated quarterly.
Also known as:
- Prostate Cancer
- Prostate Cancer Treatment (PDQ®)
- Prostatic Carcinoma
- Prostate Gland Cancer
- Malignant Prostate Tumor
ICD-10 Codes:
- C61: Malignant neoplasm of prostate
Also known as:
- Elevated PSA Level
- Prostate Cancer Screening
- Prostate Disease
- Prostate-Specific Antigen (PSA) Test
- Prostate Problems
- High Prostate Specific Antigen
- Abnormal PSA Test
- Increased PSA
ICD-10 Codes:
- R9720: Elevated prostate specific antigen [PSA]
Also known as:
- Enlarged Prostate with Urinary Symptoms
- Enlarged Prostate (BPH)
- Enlarged Prostate (Benign Prostatic Hyperplasia)
- BPH with LUTS
- Prostate enlargement with urinary issues
- Benign prostatic hyperplasia with urinary symptoms
ICD-10 Codes:
- N401: Benign prostatic hyperplasia with lower urinary tract symptoms
Also known as:
- Enlarged Prostate
- Enlarged Prostate (BPH)
- Enlarged Prostate (Benign Prostatic Hyperplasia)
- Benign Prostatic Hyperplasia
- BPH
- Prostate Enlargement
ICD-10 Codes:
- N400: Benign prostatic hyperplasia without lower urinary tract symptoms
- N402: Nodular prostate without lower urinary tract symptoms
Also known as:
- History of prostate cancer
- Prostate Cancer
- Prostate Cancer Treatment (PDQ®)
- Past prostate cancer
- Prostate cancer survivor
- Previous prostatic malignancy
ICD-10 Codes:
- Z8546: Personal history of malignant neoplasm of prostate
Also known as:
- Bladder Cancer
- Urinary Bladder Cancer
- Bladder Carcinoma
ICD-10 Codes:
- C679: Malignant neoplasm of bladder, unspecified
Also known as:
- Visible Blood in Urine
- Urine and Urination
- Hematuria (Blood in the Urine)
- Gross hematuria
- Macroscopic hematuria
- Bloody pee
ICD-10 Codes:
- R310: Gross hematuria
Also known as:
- Bladder Cancer
- Urinary Bladder Cancer
- Bladder Tumor
- Urothelial Carcinoma of Bladder
ICD-10 Codes:
- C678: Malignant neoplasm of overlapping sites of bladder
Also known as:
- Personal History of Bladder Cancer
- Bladder Cancer
- Past bladder cancer
- Previous urinary bladder malignancy
- History of bladder tumor
ICD-10 Codes:
- Z8551: Personal history of malignant neoplasm of bladder
Also known as:
- Prostate Cancer Screening
- Prostate Cancer Screening (PDQ®)
- PSA Test
- Prostate Exam
- Prostate Cancer Check
ICD-10 Codes:
- Z125: Encounter for screening for malignant neoplasm of prostate
Which procedures does Dr. Brooks perform as a Urologist?
As a Urologist, procedures performed by an Dr. James Brooks may include:
- Aesthetic Urology Consultation
- Bladder and Kidney Ultrasound
- Circumcision / Phimosis
- Cystoscopy
- Erectile Dysfunction (ED) Shockwave Therapy
- Erectile Dysfunction / Impotence / Male Sexual Dysfunction
- Evaluation of Kidney Mass
- Invasive Urologic Procedure
For detailed information, please contact Dr. Brooks' office.
Does Dr. Brooks accept my insurance?
Dr. Brooks accepts most major insurance plans. Important: Please call our office at (650) 723-4000 before your appointment to verify that your specific plan and network are accepted.
What insurance plans does Dr. Brooks accept in Stanford, CA?
Dr. Brooks in Stanford, CA accepts plans from many carriers. While this list is updated regularly, it is not a guarantee of coverage.
Top Insurances
All Other Third Party
Blue Shield of California
CVS Health (formerly Aetna)
Express Scripts
Hill Physicians Medical Group
Medicaid
Medicare
OptumRx
Santa Clara Family Health Plan
UnitedHealthcare
View All Insurances
Where is Dr. Brooks' office located?
Recognitions
Awards
Stanford University
Keith and Jan Hurlbut Professor
Best Doctors Inc.
Listing in Guide to America's Top Surgeons, Consumers' Research Counc
Stanford University School of Medicine
Leutje-Stubbs Faculty Scholar
Kidney Cancer Association
Eugene P. Schonfeld Medical Research Award
Doris Duke Foundation
Clinician Scientist Award
Dornier Research Scholar, American Foundation for Urologic Disease
Publications
tionwide prevalence of lymph node metastases in Gleason score 3?+?3?=?6 prostate cancer.
Pathology, 2014
Prostate cancer risk profiles of asian-american men
jourl of urology, 2014
Utilization of rel mass biopsy in patients with rel cell carcinoma.
Urology, 2014
Epigenetic changes in histologically normal prostate tissues.
jourl of urology, 2013
Comprehensive gene expression changes associated with mouse posttal kidney development.
jourl of urology, 2013
Uriry TMPRSS2:ERG and PCA3 in an Active Surveillance Cohort
CLINICAL CANCER RESEARCH, 2013
Treatment and mortality in men with localized prostate cancer
The Open Prostate Cancer Jourl, 2013
Identification and Characterization of 2 Testicular Germ Cell Markers, Glut3 and Cycli2.
Applied immunohistochemistry & molecular morphology : AIMM / official
A Model for the Design
ADVANCES IN ATOMIC PATHOLOGY, 2013
Maging localized prostate cancer in the era of prostate-specific antigen screening.
Cancer
Utilization of cytoreductive nephrectomy and patient survival in the targeted therapy era.
Intertiol jourl of cancer. Jourl intertiol du cancer
Higher rates of upgrading and upstaging
BJU intertiol
Differential D methylation with age displays both common
Genome biology, 2013
mR-Seq of Single Prostate Cancer Circulating Tumor Cells Reveals Recapitulation of Gene Expression
PLOS ONE, 2012
Evaluation of Putative Rel Cell Carcinoma Markers PAX-2, PAX-8
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2012
Gene Expression Changes Induced by Unilateral Ureteral Obstruction in Mice
JOURL OF UROLOGY, 2012
Methods for registration of magnetic resonce images of ex vivo prostate specimens with histology
JOURL OF MAGNETIC RESONCE IMAGING, 2012
Even-skipped homeobox 1 is frequently hypermethylated in prostate cancer
BRITISH JOURL OF CANCER, 2012
Translatiol genomics: The challenge of developing cancer biomarkers
GENOME RESEARCH, 2012
PIVOT and the challenges of localized prostate cancer care
Translatiol Andrology and Urology
The Potential Impact of Reproducibility of Gleason Grading
JOURL OF UROLOGY, 2011
D methylation profiling reveals novel biomarkers
GENOME RESEARCH, 2011
Integrated genomic alyses of ovarian carcinoma
TURE, 2011
Small Prostate Size and High Grade Disease-Biology or Artifact?
JOURL OF UROLOGY, 2011
Comparison of prostate cancer tumor volume
UROLOGIC ONCOLOGY-SEMIRS AND ORIGIL INVESTIGATIONS, 2011
Specificity of brachyury in the distinction of chordoma from clear cell rel cell carcinoma
MODERN PATHOLOGY, 2011
Length of site-specific positive surgical margins as a risk factor for biochemical recurrence
Intertiol jourl of urology : official jourl of the Japanese Urological
The distribution of PAX-2 immunoreactivity in the prostate gland, semil vesicle
HUMAN PATHOLOGY, 2010
Cary Prostate Active Surveillance Study
UROLOGY, 2010
Molecular Stratification of Clear Cell Rel Cell Carcinoma by Consensus Clustering
Genes & cancer, 2010
Gene expression changes induced by genistein in the prostate cancer cell line LNCaP
The Open Prostate Cancer Jourl, 2010
Adjuvant docetaxel and abbreviated androgen deprivation therapy
The Open Prostate Cancer Jourl, 2010
Prognostic significance of prostate cancer origiting from the transition zone
UROLOGIC ONCOLOGY-SEMIRS AND ORIGIL INVESTIGATIONS, 2009
Disorders of sex development expose transcriptiol autonomy of genetic sex and androgen
BMC GENOMICS, 2009
Alteration of Gene Expression Sigtures of Cortical Differentiation
PLOS ONE, 2009
Apolipoprotein D (APOD) is a putative biomarker of androgen receptor function in androgen
JOURL OF MOLECULAR MEDICINE-JMM, 2009
Recommendations for the Reporting of Surgically Resected Specimens of Rel Cell Carcinoma
AMERICAN JOURL OF CLINICAL PATHOLOGY, 2009
Inhibition of prostaglandin synthesis and actions by genistein
INTERTIOL JOURL OF CANCER, 2009
Recommendations for the reporting of surgically resected specimens of rel cell carcinoma The
HUMAN PATHOLOGY, 2009
STEREOTACTIC BODY RADIOTHERAPY FOR LOCALIZED PROSTATE CANCER
INTERTIOL JOURL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009
CD 9 and vimentin distinguish clear cell from chromophobe rel cell carcinoma.
BMC clinical pathology, 2009
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
TURE, 2008
Identification of candidate prostate cancer genes through comparative expression-profiling of semil
PROSTATE, 2008
Postoperative prostate
INTERTIOL JOURL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008
hCAP-D3 expression marks a prostate cancer subtype with favorable clinical behavior and androgen
AMERICAN JOURL OF SURGICAL PATHOLOGY, 2008
The impact of tumor volume on outcomes after radical prostatectomy
The Open Prostate Cancer Jourl, 2008
Genomic profiling reveals altertive genetic pathways of prostate tumorigenesis
CANCER RESEARCH, 2007
Placental S100 (S100P) and GATA3
AMERICAN JOURL OF SURGICAL PATHOLOGY, 2007
Endothelin-1 promotes cell survival in rel cell carcinoma through the ETA receptor
CANCER LETTERS, 2007
Selenomethionine induced transcriptiol programs in human prostate cancer cells
JOURL OF UROLOGY, 2007
Distinctive gene expression of prostatic stromal cells cultured from diseased versus normal tissues
JOURL OF CELLULAR PHYSIOLOGY, 2007
Cell-line and tissue-specific sigtures of androgen receptor-coregulator transcription
JOURL OF MOLECULAR MEDICINE-JMM, 2006
Application of genomic technologies to human prostate cancer
OMICS-A JOURL OF INTEGRATIVE BIOLOGY, 2006
Gene expression profiling predicts survival in conventiol rel cell carcinoma
PLOS MEDICINE, 2006
Preoperative PSA velocity is an independent prognostic factor
JOURL OF CLINICAL ONCOLOGY, 2005
Genome-wide characterization of gene expression variations
PROSTATE, 2005
Juvenile posttraumatic high-flow priapism: current magement dilemmas
JOURL OF PEDIATRIC SURGERY, 2005
A transcriptiol profile of aging in the human kidney
PLOS BIOLOGY, 2004
Molecular activity of 1
JOURL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2004
Radiotherapy after radical prostatectomy: Does transient androgen suppression improve outcomes?
INTERTIOL JOURL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004
Lower body mass index is associated with a higher prostate cancer detection rate
JOURL OF UROLOGY, 2004
Alysis of vitamin D-regulated gene expression in LNCaP human prostate cancer cells using cD
PROSTATE, 2004
Time trends in pathologic features of radical prostatectomy - impact of family history
UROLOGIC ONCOLOGY-SEMIRS AND ORIGIL INVESTIGATIONS, 2004
Gene expression in the normal adult human kidney assessed by complementary D microarray
MOLECULAR BIOLOGY OF THE CELL, 2004
Diverse effects of methylseleninic acid on the transcriptiol program of human prostate cancer cells
MOLECULAR BIOLOGY OF THE CELL, 2004
Gene expression profiling identifies clinically relevant subtypes of prostate cancer
PROCEEDINGS OF THE TIOL ACADEMY OF SCIENCES OF THE UNITED STATES OF AM, 2004
Gene expression patterns in human embryonic stem cells and human pluripotent germ cell tumors
PROCEEDINGS OF THE TIOL ACADEMY OF SCIENCES OF THE UNITED STATES OF AM, 2003
Gene expression patterns in rel cell carcinoma assessed by complementary D microarray
AMERICAN JOURL OF PATHOLOGY, 2003
Expression of FKBP12 in benign
AMERICAN JOURL OF SURGICAL PATHOLOGY, 2003
Microarray alysis in prostate cancer research.
Current opinion in urology, 2002
Novel pathways associated with bypassing cellular senescence in human prostate epithelial cells
JOURL OF BIOLOGICAL CHEMISTRY, 2002
Atomy of the rectourethralis muscle
EUROPEAN UROLOGY, 2002
Transcriptiol programs activated by exposure of human prostate cancer cells to androgen
GENOME BIOLOGY
Nationwide prevalence of lymph node metastases in Gleason score 3?+?3?=?6 prostate cancer.
Pathology, 2014
Prostate cancer risk profiles of asian-american men
journal of urology, 2014
Reply.
Urology, 2014
Utilization of renal mass biopsy in patients with renal cell carcinoma.
Urology, 2014
Increased expression of GCNT1 is associated with altered O-glycosylation of PSA, PAP
The Prostate
Evaluation of SF-1 Expression in Testicular Germ Cell Tumors
Applied immunohistochemistry & molecular morphology, 2013
Epigenetic changes in histologically normal prostate tissues.
journal of urology, 2013
Comprehensive gene expression changes associated with mouse postnatal kidney development.
journal of urology, 2013
Urinary TMPRSS2:ERG and PCA3 in an Active Surveillance Cohort
CLINICAL CANCER RESEARCH, 2013
Increased expression of NuSAP in recurrent prostate cancer is mediated by E2F1
ONCOGENE, 2013
Treatment and mortality in men with localized prostate cancer
The Open Prostate Cancer Journal, 2013
Identification and Characterization of 2 Testicular Germ Cell Markers, Glut3 and CyclinA2.
Applied immunohistochemistry & molecular morphology : AIMM / official
A Model for the Design
ADVANCES IN ANATOMIC PATHOLOGY, 2013
Managing localized prostate cancer in the era of prostate-specific antigen screening.
Cancer
Utilization of cytoreductive nephrectomy and patient survival in the targeted therapy era.
International journal of cancer. Journal international du cancer
Higher rates of upgrading and upstaging
BJU international
Differential DNA methylation with age displays both common
Genome biology, 2013
mRNA-Seq of Single Prostate Cancer Circulating Tumor Cells Reveals Recapitulation of Gene
PLOS ONE, 2012
Evaluation of Putative Renal Cell Carcinoma Markers PAX-2, PAX-8
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2012
Gene Expression Changes Induced by Unilateral Ureteral Obstruction in Mice
JOURNAL OF UROLOGY, 2012
Recurrent deletion of CHD1 in prostate cancer with relevance to cell invasiveness
ONCOGENE, 2012
Methods for registration of magnetic resonance images of ex vivo prostate specimens with histology
JOURNAL OF MAGNETIC RESONANCE IMAGING, 2012
Even-skipped homeobox 1 is frequently hypermethylated in prostate cancer
BRITISH JOURNAL OF CANCER, 2012
Performance Characteristics of Prostate
UROLOGY, 2012
Deficiency in Mammalian Histone H2B Ubiquitin Ligase Bre1 (Rnf20
CANCER RESEARCH, 2012
LONG-TERM OUTCOMES FROM A PROSPECTIVE TRIAL OF STEREOTACTIC BODY RADIOTHERAPY FOR LOW
King, C. R., Brooks, J. D., Gill, H., Presti, J. C., 2012
Translational genomics: The challenge of developing cancer biomarkers
GENOME RESEARCH, 2012
PIVOT and the challenges of localized prostate cancer care
Translational Andrology and Urology
The Potential Impact of Reproducibility of Gleason Grading
JOURNAL OF UROLOGY, 2011
DNA methylation profiling reveals novel biomarkers
GENOME RESEARCH, 2011
Integrated genomic analyses of ovarian carcinoma
NATURE, 2011
Small Prostate Size and High Grade Disease-Biology or Artifact?
JOURNAL OF UROLOGY, 2011
A Tri-Marker Proliferation Index Predicts Biochemical Recurrence after Surgery for Prostate Cancer
PLOS ONE, 2011
Comparison of prostate cancer tumor volume
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2011
Specificity of brachyury in the distinction of chordoma from clear cell renal cell carcinoma
MODERN PATHOLOGY, 2011
Length of site-specific positive surgical margins as a risk factor for biochemical recurrence
International journal of urology : official journal of the Japanese Ur
Smoking and adverse outcomes at radical prostatectomy.
Urologic oncology
The distribution of PAX-2 immunoreactivity in the prostate gland, seminal vesicle
HUMAN PATHOLOGY, 2010
Canary Prostate Active Surveillance Study
UROLOGY, 2010
Molecular Stratification of Clear Cell Renal Cell Carcinoma by Consensus Clustering Reveals
Genes & cancer, 2010
Gene expression changes induced by genistein in the prostate cancer cell line LNCaP
The Open Prostate Cancer Journal, 2010
Adjuvant docetaxel and abbreviated androgen deprivation therapy
The Open Prostate Cancer Journal, 2010
Prognostic significance of prostate cancer originating from the transition zone
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2009
Disorders of sex development expose transcriptional autonomy of genetic sex and androgen
BMC GENOMICS, 2009
Alteration of Gene Expression Signatures of Cortical Differentiation
PLOS ONE, 2009
Apolipoprotein D (APOD) is a putative biomarker of androgen receptor function in androgen
JOURNAL OF MOLECULAR MEDICINE-JMM, 2009
Prostatic Soy Isoflavone Concentrations Exceed Serum Levels After Dietary Supplementation
PROSTATE, 2009
Recommendations for the Reporting of Surgically Resected Specimens of Renal Cell Carcinoma
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2009
Inhibition of prostaglandin synthesis and actions by genistein
INTERNATIONAL JOURNAL OF CANCER, 2009
Recommendations for the reporting of surgically resected specimens of renal cell carcinoma The
HUMAN PATHOLOGY, 2009
STEREOTACTIC BODY RADIOTHERAPY FOR LOCALIZED PROSTATE CANCER
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009
Temporal Changes in Gene Expression Induced by Sulforaphane in Human Prostate Cancer Cells
PROSTATE, 2009
CD 9 and vimentin distinguish clear cell from chromophobe renal cell carcinoma.
BMC clinical pathology, 2009
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
NATURE, 2008
Identification of candidate prostate cancer genes through comparative expression
PROSTATE, 2008
Postoperative prostate
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008
hCAP-D3 expression marks a prostate cancer subtype with favorable clinical behavior and androgen
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2008
The impact of tumor volume on outcomes after radical prostatectomy
The Open Prostate Cancer Journal, 2008
Intrinsic androgen-dependent gene expression patterns revealed by comparison of genital fibroblasts
BMC GENOMICS, 2007
Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis
CANCER RESEARCH, 2007
Placental S100 (S100P) and GATA3
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2007
A promoting role of androgen receptor in androgen-sensitive and -insensitive prostate cancer cells
NUCLEIC ACIDS RESEARCH, 2007
A variant TMPRSS2 isoform
MODERN PATHOLOGY, 2007
Endothelin-1 promotes cell survival in renal cell carcinoma through the ETA receptor
CANCER LETTERS, 2007
Selenomethionine induced transcriptional programs in human prostate cancer cells
JOURNAL OF UROLOGY, 2007
Distinctive gene expression of prostatic stromal cells cultured from diseased versus normal tissues
JOURNAL OF CELLULAR PHYSIOLOGY, 2007
Cell-line and tissue-specific signatures of androgen receptor-coregulator transcription
JOURNAL OF MOLECULAR MEDICINE-JMM, 2006
Application of genomic technologies to human prostate cancer
OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY, 2006
Reliability of small amounts of cancer in prostate biopsies to reveal pathologic grade
UROLOGY, 2006
Refractory hematuria from amyloidosis successfully treated by splenectomy
UROLOGY, 2006
Modest induction of phase 2 enzyme activity in the F-344 rat prostate
BMC CANCER, 2006
Gene expression profiling predicts survival in conventional renal cell carcinoma
PLOS MEDICINE, 2006
The retinoic acid synthesis gene ALDH1a2 is a candidate tumor suppressor in prostate cancer
CANCER RESEARCH, 2005
Preoperative PSA velocity is an independent prognostic factor
JOURNAL OF CLINICAL ONCOLOGY, 2005
Genome-wide characterization of gene expression variations
PROSTATE, 2005
Juvenile posttraumatic high-flow priapism: current management dilemmas
JOURNAL OF PEDIATRIC SURGERY, 2005
Reg IV: A promising marker of hormone refractory metastatic prostate cancer
CLINICAL CANCER RESEARCH, 2005
Resveratrol-induced gene expression profiles in human prostate cancer cells
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2005
Molecular targets of Doxazosin in human prostatic stromal cells
PROSTATE, 2005
Positive family history of prostate cancer not
UROLOGY, 2005
Microarray Data Mining for Potential Selenium Targets in Chemoprevention of Prostate Cancer.
Cancer genomics & proteomics, 2005
A transcriptional profile of aging in the human kidney
PLOS BIOLOGY, 2004
Vascular invasion predicts recurrence after radical prostatectomy
UROLOGY, 2004
Molecular activity of 1
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2004
Radiotherapy after radical prostatectomy: Does transient androgen suppression improve outcomes?
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004
Lower body mass index is associated with a higher prostate cancer detection rate
JOURNAL OF UROLOGY, 2004
Analysis of vitamin D
PROSTATE, 2004
Time trends in pathologic features of radical prostatectomy - impact of family history
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2004
Biochemical remission after resection of prostate cancer lung metastasis
UROLOGY, 2004
Gene expression in the normal adult human kidney assessed by complementary DNA microarray
MOLECULAR BIOLOGY OF THE CELL, 2004
Diverse effects of methylseleninic acid on the transcriptional program of human prostate cancer
MOLECULAR BIOLOGY OF THE CELL, 2004
Gene expression profiling identifies clinically relevant subtypes of prostate cancer
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES O, 2004
Gene expression patterns in human embryonic stem cells and human pluripotent germ cell tumors
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES O, 2003
Gene expression patterns in renal cell carcinoma assessed by complementary DNA microarray
AMERICAN JOURNAL OF PATHOLOGY, 2003
Biochemical recurrence without PSA progression characterizes a subset of patients after radical
UROLOGY, 2003
Differential gene-expression patterns in genital fibroblasts of normal males and 46
GENOME BIOLOGY, 2003
Expression of FKBP12 in benign
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2003
Identification of potential prostate cancer preventive agents through induction of quinone reduct
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2002
Polymorphisms in the androgen receptor and type II 5 alpha
PROSTATE, 2002
Microarray analysis in prostate cancer research.
Current opinion in urology, 2002
Silencing of pi-class glutathione S-transferase in MDA PCa 2a and MDA PCa 2b cells
PROSTATE, 2002
Novel pathways associated with bypassing cellular senescence in human prostate epithelial cells
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002
Anatomy of the rectourethralis muscle
EUROPEAN UROLOGY, 2002
Transcriptional programs activated by exposure of human prostate cancer cells to androgen
GENOME BIOLOGY
What is Dr. Brooks's NPI number?An National Provider Identifier (NPI) is a unique ID number that identifies doctors and healthcare providers nationwide.
Dr. Brooks's National Provider Identifier (NPI) number is 1043320005.
What common questions do patients ask about Dr. Brooks?
Here are answers to patients Frequently Asked Questions (FAQ’s) about Dr. Brooks
What is Dr. James Brooks's specialty?
Dr. Brooks is a Urologist near Stanford, CA. A urologist is a healthcare professional with specialization in managing both benign and malignant medical and surgical disorders of the genitourinary system and adrenal glands. They possess extensive knowledge and skills in endoscopic, percutaneous, and open surgical techniques for addressing congenital and acquired conditions of the urinary and reproductive systems, as well as their associated structures. Contact Dr. Brooks to book an appointment today.
Is this Dr. James Brooks affiliated with a ranked Castle Connolly Top Hospital?
Yes, Dr. Brooks is affiliated with Stanford Health Care - Stanford Hospital which is a Castle Connolly Top Hospital. Castle Connolly Top Hospitals are healthcare institutions recognized for their excellence in specific medical procedures and overall patient care. They are identified through a rigorous peer nomination process, evaluating factors like patient outcomes, quality of care, and expertise. The list recognizes hospitals that excel in 20 or more specific medical procedures, representing the top 25% nationwide. Castle Connolly Top Hospitals
Where can I learn more about Urologist?
Explore Urologist with insights from trusted medical experts on EverydayHealth.com, where you'll find the most relevant content and helpful condition guides for up-to date information about symptoms, causes, diagnosis, treatment and more. See all our health guides to find trusted information on medical conditions from our experts at Everyday Health.
Is James Brooks accepting new patients in Stanford, CA?
Yes, Dr. James Brooks is accepting new patients at this time.
Does Dr. James Brooks offer online booking?
Please contact Dr. Brooks's office at (650) 723-4000 for information about online booking, telehealth, or to schedule an appointment.
How can I make an appointment with James Brooks?
Please contact Dr. Brooks's office at (650) 723-4000 for information regarding telehealth appointment availability or for scheduling assistance.
Which board certifications does Dr. James Brooks have?
Dr. James Brooks is certified by the American Board of Urology.
Other Urologist Near Stanford, CA
Urologist
Accepting patientsUrologist
Accepting patientsUrologist
Accepting patients